(Circulation. 2001;104:2905.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Laboratory of Chemical Physics (K.J.Z., M.D.S., I.W.L.), National Institute of Diabetes and Digestive and Kidney Diseases; the Critical Care Medicine Department, (M.T.G.) Warren G. Magnuson Clinical Center; and the Cardiology Branch (R.O.C.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda Md.
Correspondence to Ira W. Levin, PhD, Laboratory of Chemical Physics, NIDDK, National Institutes of Health, Building 5, Room B1-32, 9000 Rockville Pike, Bethesda, MD 20892-0510. E-mail iwl{at}helix.nih.gov
| Abstract |
|---|
|
|
|---|
Methods and Results To simulate vascular endothelial dysfunction, NG-monomethyl-L-arginine (L-NMMA) was infused into the brachial arteries of 9 healthy subjects for 5 minutes to inhibit forearm NO synthesis, first with the subject breathing room air and subsequently during NO inhalation at 80 ppm for 1 hour. Blood flow was measured by venous occlusion plethysmography, and the percentage of HbO2 perfusing skin tissue was imaged noninvasively with a visible-reflectance hyperspectral technique. L-NMMA reduced blood flow by 31.7±4.9% and percentage of HbO2 by 6.5±0.1 (P=0.002 and P<0.001 versus baseline, respectively). With subjects inhaling NO, blood flow fell during L-NMMA infusion by only 10.9±7.3%, and the percentage of HbO2 decreased by 3.6±0.1 (P=0.007 and P<0.001, respectively, versus room air L-NMMA responses).
Conclusions Visible-reflectance hyperspectral imaging demonstrates (1) a significant decline in the percentage of HbO2 in skin tissue when blood flow is reduced after inhibition of forearm NO synthesis and (2) restoration of HbO2 toward basal values with improved blood flow during inhalation of NO. This imaging method may provide an effective approach for time-resolved noninvasive monitoring of skin hemoglobin oxygen saturation and assessment of responses to therapeutic interventions in patients with vascular disease.
Key Words: peripheral vascular disease blood flow nitric oxide hemoglobin imaging
| Introduction |
|---|
|
|
|---|
Hemoglobin oxygen saturation may be measured by oximeters, although these devices are somewhat limited in usage. For example, a 2-wavelength transmission device restricts measurements to a single point, by which light is passed through either the finger or earlobe.6 For application to other parts of the body (as, for example, the chest, forehead, or limbs), a transcutaneous reflectance oximeter was developed and further adapted to a 5-wavelength spectral range.7,8 This particular class of oximeters also introduced additional optical methods for clinically measuring changes in tissue oxygen saturation in patients.914
Recent developments in focal-plane-array detectors for spectroscopic imaging and in the incorporation of improved charge-coupled device (CCD) detectors, along with the implementation of liquid crystal tunable filters for spectroscopic wavelength access, support the feasibility of noninvasive hyperspectral imaging approaches in humans.1521 In particular, the visible-reflectance imaging modality allows spatially relevant spectroscopic data to be recorded easily and rapidly from human subjects. With present-day computational power allowing multivariate spectrometric image analyses to be completed within a relatively short period of time, an effective and highly adaptable instrument may be designed with the potential for monitoring broad aspects of tissue perfusion. The hyperspectral technique measures spectral changes within the visible spectrum of light and provides information on the molecular state of hemoglobin; in contrast, Doppler imaging measures ultrasound frequency shifts22 or wavelength shifts in the case of laser-Doppler methods.23
| Methods |
|---|
|
|
|---|
|
Spectroscopic Determination of Percentage of HbO2
To determine the feasibility of the visible-reflectance hyperspectral imaging system for determining real-time changes in the percentage of HbO2, vascular dysfunction and its treatment were simulated by regional NO synthase (NOS) inhibition, followed by NO inhalation. A quartz tungsten halogen light source illuminates the subject via collimating optics and liquid light guides (Oriel Instruments) (Figure 1a). A mirror guides the diffuse sample reflectance to a liquid crystal tunable filter (Cambridge Research and Instrumentation) and lens (Nikon), which focuses the spectrally filtered image onto the CCD detector (Roper Scientific). A computer program run on an Optiplex GX1P computer (Dell) manages the data acquisition by tuning the liquid crystal tunable filter, triggering the CCD detector, and writing the data to disk.
The measured reflectance spectra are quantified in terms of apparent absorbance, which is a ratio of the reflected sample radiation to the reflected radiation from a certified standard (SRT-99-120; Labsphere).10,12,25,26 These data are formatted as a hyperspectral image cube, which defines a series of images at multiple, contiguous wavelengths representative of narrow spectral bandwidths. Spectra obtained at each pixel of the image cube are deconvolved by a multivariate least-squares regression analysis.27
Reference spectra of a 100% HbO2 and deoxy-Hb, used to deconvolve a measured spectrum at each pixel, were prepared with standard methods using blood collected from a healthy, nonsmoking individual.28 Seven milliliters of hemolysates was mixed with 30 mg of sodium dithionite to yield the pure deoxy-Hb sample (Figure 1b). The HbO2 spectrum displays distinct peaks at 541 and 576 nm, whereas the pure deoxy-Hb displays a single peak at 555 nm.11,12
Study Population
The study group consisted of 9 nonsmoking healthy volunteer subjects (5 men and 4 women) with an average age of 32±4 years. Each subject was screened by clinical history, physical examination, ECG, and routine laboratory analyses and had no evidence of cardiovascular disease or other systemic condition. The Institutional Review Board of the National Heart, Lung, and Blood Institute approved this study, and all participants provided written, informed consent for all procedures.
Protocol
Subjects fasted overnight and refrained from drinking alcohol and beverages containing caffeine for
12 hours. All studies were conducted in the morning in a quiet room set at a temperature of
22°C. While the subject breathed room air, an infusion of 5% dextrose in water (D5W) was started for 20 minutes, after which baseline measures were acquired, followed by switching the D5W infusion for NG-monomethyl-L-arginine (L-NMMA). Subsequently, NO was inhaled for 120 minutes, and D5W was infused for the last 20 minutes of this period. While the subjects continued to inhale NO, baseline measures were acquired, and then the D5W infusion was switched to L-NMMA.
Forearm blood flow was measured by venous occlusion plethysmography (Hokanson).29 Briefly, this method occludes the venous drainage of the forearm. From the rate of increase in the blood volume, the proportional arterial blood flow is determined. Hyperspectral and blood flow measurements were made at baseline during infusion of D5W at 1 mL/min into the brachial artery. Vascular dysfunction was simulated pharmacologically by infusion of the NOS inhibitor L-NMMA at 4 to 8 µmol/min into the brachial artery to inhibit NO synthesis and reduce forearm blood flow.29 We recently reported that L-NMMA infused into the brachial artery of healthy subjects reduces not only forearm blood flow but also antecubital venous PO2 and pH, consistent with reduced tissue oxygenation and acidosis.30 Hyperspectral measurements were obtained continuously during the L-NMMA infusion, and blood measurements were performed after 5 minutes of L-NMMA infusion.
Treatment of vascular dysfunction was simulated by the inhalation of NO in the presence of NOS inhibition by a repeat infusion of L-NMMA. NO was delivered at 80 ppm via an anesthesia face mask with a reservoir bag (FIO2=0.21) with the Ohmeda NO delivery system (Datex-Ohmeda) with intra-arterial infusion of D5W at 1 mL/min. After 1 hour of NO inhalation, hyperspectral and blood flow measurements were made. With continuation of NO breathing, the L-NMMA infusion was repeated, during which time hyperspectral images were collected, and after 5 minutes, blood flow measurements were acquired.
Statistical Analysis
Differences between population means were compared by a 2-tailed, paired Students t test. Percentages of HbO2 image data were determined from a multivariate least-squares deconvolution of the hyperspectral data cube; a sampling of 1089 binned detector pixels was used to define a 5-cm2 rectangular area within the palm of the hand. All data are reported as mean±SEM.
| Results |
|---|
|
|
|---|
After 1 hour of NO inhalation, basal forearm blood flow was 2.5±0.4 mL · min-1 · 100 mL tissue-1. Continuation of NO inhalation and reinfusion of L-NMMA at the same dosage as used during room air breathing resulted in a blood flow of 2.1±0.3 mL · min-1 · 100 mL tissue-1, a reduction of only 0.3±0.2 mL · min-1 · 100 mL tissue-1 (P=0.101 versus baseline). This reduction in blood flow from baseline in response to L-NMMA infusion during NO breathing was significantly less than the L-NMMA-induced vasoconstriction with the subject breathing room air (Figure 2).
|
The basal percentage of HbO2 measured by the visible-reflectance hyperspectral imaging technique with subjects breathing room air was 79.8±0.1. Infusion of L-NMMA with the subject breathing room air decreased the percentage of HbO2 to 73.3±0.1, a reduction of 6.5±0.1 (P<0.001 versus baseline). The basal percentage of HbO2 with the subject inhaling NO was 79.7±0.1. L-NMMA infusion during continued NO inhalation reduced the percentage of HbO2 to 76.1±0.1, a reduction of 3.6±0.1 (P<0.001 versus baseline). The magnitude of the L-NMMA effect on blood flow and the percentage of HbO2 was less during NO inhalation than room air inhalation (Figure 2).
Time-Resolved Visible, Hyperspectral Measurement of the Percentage of HbO2 During L-NMMA Infusion in the Absence and Presence of NO
For 3 subjects, we determined a time-resolved, hyperspectral measurement that exhibited a stepwise decrease in percentage of HbO2: 78.5±1.5 at 1.5 minutes, 74.7±1.8 at 3.0 minutes, and 72.0±1.9 at 4.5 minutes, during the 5-minute infusion of L-NMMA while the subject breathed room air (Figure 3). During the repeat L-NMMA infusion while subjects inhaled NO, the reduction in percentage of HbO2 was significantly less, with values of 79.0±0.5 at 1.5 minutes, 77.6±1.3 at 3.0 minutes, and 76.8±0.7 at 4.5 minutes.
|
Hyperspectral Imaging Illustrates Both Spectral and Spatial Capabilities in Noninvasive Monitoring of Skin Tissue Oxygenation
The acquisition of visible-reflectance hyperspectral images for assessing vascular percentage of HbO2 changes during L-NMMA infusion permits actual visualization of the effects of reduced tissue perfusion within skin. For example, the white-light image of the palm of the hand displays only general morphological features (Figure 4a), whereas the digital gray-scale hyperspectral images (Figure 4b and 4c) display the spatial distribution of the percentage of HbO2 across the palm of the hand during different states of skin perfusion. Specifically, the basal hyperspectral image (Figure 4b) represents the resting state during which the percentages of HbO2 across the hand are determined to be at normal levels, with HbO2 being distributed relatively homogeneously. The brighter intensity of a given pixel indicates an increased percentage of HbO2. As an example of the determination of spectra from a given spatially resolved domain in a subjects hand, spectroscopic data from 10 detector pixels were averaged, yielding predominantly oxyhemoglobin, as indicated by spectrum 1 and by the overall bright pixel intensities (Figure 4b). After the infusion of L-NMMA, the image again displays the percentage of HbO2 as a spatial variable (Figure 4c). This is now visualized more dramatically as an inhomogeneous distribution of pixel intensities, which is confirmed by the visible spectra. Spectrum 2 (Figure 4c), which was collected from a darker region, is seen to have a low percentage of HbO2 (and a high percentage of deoxy-Hb) compared with spectra 3 and 4, which were collected from brighter pixel regions and exhibit increases in percentage of HbO2.
|
The set of time-resolved images (Figure 5) demonstrates the effects of L-NMMA infusion on skin HbO2 as a function of time. The overall intensity of the hand at baseline while the subject breathed room air (Figure 5, 1a) indicates greater percentages of HbO2 than while the L-NMMA was infused into the forearm for 4.5 minutes (Figure 5, 1d). This image exhibits darker pixels and indicates diminished percentages of HbO2. The decrease in image intensity (Figure 5, 1a through 1d) translates to the 6.5±0.1 reduction in percentage of HbO2 determined by hyperspectral imaging from a basal level and is associated with the 31.7±4.9% reduction in blood flow, as measured by venous occlusion plethysmography, in which the reduction in blood flow results from inhibition of endothelial synthesis of NO by L-NMMA.
|
The overall pixel intensity of the hand during NO inhalation at baseline (Figure 5, 2a) is slightly brighter than the hand infused with L-NMMA for 4.5 minutes during NO inhalation (Figure 5, 2d). The reflectance hyperspectral data agree with the measured 3.6±0.1 reduction in percentage of HbO2 associated with a 10.9±7.3% reduction in forearm blood flow (Figure 2). The gray-scale image obtained while L-NMMA was infused and the subject inhaled NO (Figure 5, 2d) is also brighter than the image of the hand during L-NMMA infusion with the subject breathing room air (Figure 5, 1d).
The time progression and spatial resolution of HbO2 from the effects of L-NMMA infusion with the subject breathing room air (Figure 5, 1b through 1d) is further elucidated by a grid overlaid on the image of the hand (Figure 6a), which provides a spatial reference for tracking the changes in percentage of HbO2 over time. Each square, numbered sequentially (Figure 6b) within the grid, contains 100 pixels (10x10). The averages of specific grid locations are plotted as a function of time in Figure 6c.
|
| Discussion |
|---|
|
|
|---|
We implemented the imaging device to collect data while monitoring vascular functional changes that were induced pharmacologically in human subjects. Thus, visible-reflectance hyperspectral image data were acquired in 2 ways: (1) before and during infusion of L-NMMA into the brachial artery, causing vasoconstriction with the subject breathing room air, and then before and during reinfusion of L-NMMA while subjects inhaled NO; and (2) continuously during the L-NMMA infusion into the brachial artery over a 5-minute period to monitor the changes in the percentage of HbO2 due to reduction in blood flow as a function of time. We determined that the percentage of HbO2 was reduced significantly while L-NMMA was administered into the forearm and then increased toward basal levels during reinfusion of L-NMMA while subjects inhaled NO. The time-resolved measurements indicate a stepwise decrease in the percentage of HbO2 over time in response to L-NMMA infusion with the subject breathing room air. The rate of this decrease, which is reduced with NO inhalation, is clearly a function of spatial location, with the greatest reduction in percentage of HbO2 visualized over the more muscular portions of the hand, namely the thenar and hypothenar eminences. This inhomogeneity of reduction in percentage of HbO2 at different time points during L-NMMA infusion may reflect anatomic variations of the vasculature of the palm. The data determined from hyperspectral images of HbO2 were associated with blood flow, measured in our study by venous occlusion plethysmography. Thus, infusion of L-NMMA, an NOS inhibitor, resulted not only in reduced forearm blood flow but also in diminished skin tissue oxygenation. Furthermore, inhalation of NO in gas form largely prevented vasoconstriction associated with regional NOS inhibition and improved tissue oxygenation. The increase in the percentage of HbO2 during L-NMMA infusion and NO inhalation is consistent with NO delivery in blood from the lungs to the vasculature, thus improving the vasodilator tone and perfusion.30
Noninvasive techniques for providing rapid, repetitive assessment of tissue perfusion could be of considerable utility in the management of a variety of vascular diseases. In addition to assessing and quantifying the concentration of a specific chemical species, such as HbO2 and deoxy-Hb, hyperspectral imaging provides representations of the spatial distribution of a molecular species at a given time or over time. Accordingly, acquisition of a time-resolved profile representing the spatial dynamics of physiologically important molecules indicative of tissue perfusion could prove useful in assessing the efficacy of a given therapeutic intervention on vascular disease.
| Acknowledgments |
|---|
Received July 19, 2001; revision received October 10, 2001; accepted October 10, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. T. Gladwin, N. J. H. Raat, S. Shiva, C. Dezfulian, N. Hogg, D. B. Kim-Shapiro, and R. P. Patel Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2026 - H2035. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. McMahon and A. Doctor Extrapulmonary effects of inhaled nitric oxide: role of reversible s-nitrosylation of erythrocytic hemoglobin. Proceedings of the ATS, January 1, 2006; 3(2): 153 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Zuzak, M. T. Gladwin, R. O. Cannon III, and I. W. Levin Imaging hemoglobin oxygen saturation in sickle cell disease patients using noninvasive visible reflectance hyperspectral techniques: effects of nitric oxide Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1183 - H1189. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |